Lori Anne Kunkel - 19 May 2025 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Director
Issuer ticker: NRIX
Reported as of: 19 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2025, 17:33:36 UTC
Prior SEC filing: 04 Mar 2025
Next SEC filing: 05 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Daniel Burbach, as Attorney-in-Fact for Lori Ann Kunkel

Key filing fact

Lori Anne Kunkel filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 19 May 2025.

Key facts

This page summarizes Lori Anne Kunkel's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 May 2025, 17:33.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001536368 Primary reporting owner

Kunkel Lori Anne

Relationship: Director
Address: C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Lori Ann Kunkel
Signature date: 19 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 19 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $9.51
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.